

Review of: "Resectable Pancreatic Cancer With Peritoneal Metastases: Is Cytoreduction Combined With Hipec Effective and When?"

Giuseppe Giuliani¹

¹ Ospedale Misericordia di Grosseto

Potential competing interests: No potential competing interests to declare.

Thanks for the opportunity to review this article.

Just a few questions:

Why were only primary pancreatic cancers located in the tail of the pancreas selected?

In the results, you wrote "Complete cytoreduction (CC-0) was possible in 11 cases": I did not understand, is it 10 or 11? Is it a mistake, or did I not understand the sentence?

In the follow-up, you write: "1 patient (9.1%) remains alive without disease 38 months after initial treatment, 5 (45.5%) died because of disease recurrence, 1 patient (9.1%) died because of reasons unrelated to the disease, and 4 patients (36.4%) are alive with disease recurrence." Also in this sentence, it seems that the patients are 11. Please be more specific. Also, do your results include the two patients who died on postoperative days 5 and 6?

Thank you for the opportunity to review this interesting study, and congratulations on the paper.